SPONSOR

City of Hope Medical Center

Total Trials

Recruiting

Phases

Phase 1, Phase 2, Phase 1, Phase 2, Phase 3

Conditions studied: B-Cell Non-Hodgkin Lymphoma Diffuse Large B-Cell Lymphoma Mantle Cell Lymphoma Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Transformed Non-Hodgkin Lymphoma Transformed Non-Hodgkin Lymphoma Appendiceal Cancer Appendiceal Adenocarcinoma

City of Hope Medical Center is a clinical research sponsor with 22 registered studies on ClinicalTrials.gov, of which 22 are actively recruiting participants. Research covers conditions including B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma.

The trial portfolio spans Phase 1, Phase 2, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — City of Hope Medical Center

How many clinical trials has City of Hope Medical Center sponsored?

ClinicalMetric currently tracks 22 clinical trials sponsored by City of Hope Medical Center, of which 22 are actively recruiting participants. These trials cover conditions including B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does City of Hope Medical Center research focus on?

City of Hope Medical Center clinical trials span B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, and additional conditions. The research pipeline includes Phase 1, Phase 2, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a City of Hope Medical Center clinical trial?

To participate in a City of Hope Medical Center trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all City of Hope Medical Center trials with current recruitment status updated daily.

City of Hope Medical Center

Frequently Asked Questions — City of Hope Medical Center

Clinical Trials by City of Hope Medical Center

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

Molecular Profiling for Risk Stratification in Appendiceal Cancer

Provider-Mediated Communication of Genetic Testing Results to At-Risk Relatives of Cancer Patients to Improve Genetic Counseling and Testing Rates, Family HOPE Study

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer

Pancreatic Cancer Detection Consortium

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer

Aromatherapy Essential Oils to Manage Anxiety and Nausea in Cancer Patients Receiving Infusion in the Ambulatory Setting

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma

Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Biospecimen Analysis in Detecting Chemical Concentrations in Patients With Chronic or Infectious Diseases Receiving Meditations

Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer

Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Improving Islet Transplantation Outcomes With Gastrin for Type I Diabetes

Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy